Cellectis (NASDAQ:CLLS) Stock Rating Lowered by StockNews.com

Cellectis (NASDAQ:CLLS) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a report released on Monday.

Cellectis Stock Performance

Cellectis stock opened at $1.41 on Monday. The firm’s 50 day simple moving average is $1.37 and its 200-day simple moving average is $1.59. The company has a market cap of $78.37 million, a P/E ratio of -1.08 and a beta of 3.11. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78. Cellectis has a fifty-two week low of $1.10 and a fifty-two week high of $3.10.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.03). Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The company had revenue of $12.03 million for the quarter, compared to analysts’ expectations of $12.71 million. As a group, equities research analysts predict that Cellectis will post -0.46 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CLLS. B Group Inc. purchased a new position in Cellectis during the fourth quarter valued at approximately $5,547,000. Millennium Management LLC purchased a new position in Cellectis during the fourth quarter valued at approximately $962,000. Finally, Wells Fargo & Company MN grew its position in Cellectis by 103.4% in the fourth quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 12,500 shares in the last quarter. 63.90% of the stock is owned by hedge funds and other institutional investors.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.